Adagio Therapeutics, Inc. (ADGI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADGI Stock Price Chart Interactive Chart >
ADGI Price/Volume Stats
| Current price | $4.64 | 52-week high | $78.82 |
| Prev. close | $4.60 | 52-week low | $2.41 |
| Day low | $4.40 | Volume | 536,300 |
| Day high | $4.74 | Avg. volume | 2,269,922 |
| 50-day MA | $4.13 | Dividend yield | N/A |
| 200-day MA | $6.92 | Market Cap | 504.98M |
Adagio Therapeutics, Inc. (ADGI) Company Bio
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.
Latest ADGI News From Around the Web
Below are the latest news stories about ADAGIO THERAPEUTICS INC that investors may wish to consider to help them evaluate ADGI as an investment opportunity.
Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron VariantsIntegrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern (e.g., D614G, beta, delta) and Omicron sublineages BA.1, BA.2, BA.4, BA.5 and BA.2.75, as well as SARS-CoV-1Antibodies target highly conserved epitopes under low immune pressure NVD200, a novel combination of two monoclonal antibodies, expected to advance into clinical trials in Q1 2023 WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, |
Adagio Therapeutics Announces Corporate Name Change to InvivydNew name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally occurring immunityThe Invivyd corporate mission is to provide antibody solutions that provide superior protection against viral diseases, starting with COVID-19Company’s shares to trade under new ticker symbol “IVVD” starting on September 13 WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, (Nasdaq: ADGI), a clinical-stage |
Adagio Therapeutics to Participate in Upcoming Investor ConferencesWALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases, today announced participation in the following upcoming investor conferences: Morgan Stanley 20th Annual Global Healthcare Conference: Management will participate in a fireside chat on Monday, September 12, 2022, at 2:50 |
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and Treatment with Plans to Enter Clinical Trials in the First Quarter of 2023 WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infecti |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, investor! |
ADGI Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 23.73% |
| 1-year | -35.38% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...